Kidney Week

Basic/Clinical Science Session

SGLT2 Inhibition for CKD: Results of the DAPA-CKD Trial

October 23, 2020 | 02:30 PM - 03:30 PM

Location: Live-Streamed

Session Description

The DAPA-CKD trial assessed the SGLT2 inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). The trial was stopped early for overwhelming efficacy. This session presents the results of the DAPA-CKD trial with a focus on patients without T2D.

Learning Objective(s)

• Discuss mechanisms of action of SGLT2 inhibitors in patients with and without T2D
• Describe the DAPA-CKD trial design and highlight differences from other trials
• Discuss the DAPA-CKD trial results with a focus on patients without T2D

Learning Pathway(s)

• Chronic Kidney Disease
• Diabetes and Metabolism

Presentations

• Rationale and Design of the DAPA-CKD Trial
  02:30 PM - 02:50 PM
  Hiddo Jan L Heerspink, PhD 
  
  

  Hiddo Jan L Heerspink, PhD

Rationale and Design of the DAPA-CKD Trial

October 23, 2020 | 02:30 PM - 02:50 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Results of the DAPA-CKD Trial
  02:50 PM - 03:10 PM
  David C. Wheeler, MD
  

  David C. Wheeler, MD

Results of the DAPA-CKD Trial

October 23, 2020 | 02:50 PM - 03:10 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.

• Clinical Perspective on the DAPA-CKD Trial
  03:10 PM - 03:30 PM
  Robert D. Toto, MD
  

  Robert D. Toto, MD

Clinical Perspective on the DAPA-CKD Trial

October 23, 2020 | 03:10 PM - 03:30 PM

Click an icon below to load this item into your calendar. Please note that times are exported as Coordinated Universal Time (UTC). Time zone help.